METOPROLOL SUCCINATE E/R- metoprolol succinate tablet, extended release

Nazione: Stati Uniti

Lingua: inglese

Fonte: NLM (National Library of Medicine)

Principio attivo:

METOPROLOL SUCCINATE (UNII: TH25PD4CCB) (METOPROLOL - UNII:GEB06NHM23)

Commercializzato da:

DirectRX

INN (Nome Internazionale):

METOPROLOL SUCCINATE

Composizione:

METOPROLOL TARTRATE 50 mg

Via di somministrazione:

ORAL

Tipo di ricetta:

PRESCRIPTION DRUG

Indicazioni terapeutiche:

- 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a var

Stato dell'autorizzazione:

Abbreviated New Drug Application

Scheda tecnica

METOPROLOL SUCCINATE E/R- METOPROLOL SUCCINATE TABLET, EXTENDED
RELEASE
DIRECTRX
----------
METOPROLOL SUCCINATE
BOXED WARNING SECTION
WARNING: ISCHEMIC HEART DISEASE: Following abrupt cessation of therapy
with
certain beta-blocking agents, exacerbations of angina pectoris and, in
some cases, myocardial
infarction have occurred. When discontinuing chronically administered
metoprolol succinate
extended-release, particularly in patients with ischemic heart
disease, the dosage should be
gradually reduced over a period of 1 to 2 weeks and the patient should
be carefully monitored.
If angina markedly worsens or acute coronary insufficiency develops,
metoprolol succinate
extended-release administration should be reinstated promptly, at
least temporarily, and other
measures appropriate for the management of unstable angina should be
taken. Warn patients
against interruption or discontinuation of therapy without the
physician’s advice. Because
coronary artery disease is common and may be unrecognized, it may be
prudent not to
discontinue metoprolol succinate extended-release therapy abruptly
even in patients treated
only for hypertension (5.1).
INDICATIONS & USAGE SECTION
1.1 Hypertension
Metoprolol succinate extended-release tablets are indicated for the
treatment of hypertension, to
lower blood pressure. Lowering blood pressure lowers the risk of fatal
and non-fatal
cardiovascular events, primarily strokes and myocardial infarctions.
These benefits have been seen
in controlled trials of antihypertensive drugs from a wide variety of
pharmacologic classes
including metoprolol.
Control of high blood pressure should be part of comprehensive
cardiovascular risk management,
including, as appropriate, lipid control, diabetes management,
antithrombotic therapy, smoking
cessation, exercise, and limited sodium intake. Many patients will
require more than 1 drug to
achieve blood pressure goals. For specific advice on goals and
management, see published
guidelines, such as those of the National High Blood Pressure
Education Prog